Amyloid fibril formation and protein misassembly: A structural quest for insights into amyloid and priori diseases

Structure

Volumn 5, Issue 5, 1997, Pages 595-600

  Kelly, Jeffery W ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031570336     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(97)00215-3     Document Type: Review

References (73)

1. Lansbury, P.T. (1992). In pursuit of the molecular structure of the amyloid plaque: new technology provides unexpected and critical information. Biochemistry 31, 6865-6870.
2. Blake, C. & Serpell, L. (1996). Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix. Structure 4, 989-998.
3. Ghadiri, M.R., Kobayashi, K., Granja, J.R., Chadha, R.K. & McRee, D.E. (1995). Structural and thermodynamic basis for the formation of self-assembled peptide nanotubes. Angew. Chem. Int. Ed. 34, 93-95.
4. Bennett, M.J., Choe, S. & Eisenberg, D. (1994). Domain swapping: entangling alliances between proteins. Proc. Natl. Acad. Sci. USA 91, 3127-3131.
5. Bennett, M.J., Schlunegger, M.P. & Eisenberg, D. (1995). 3D-domain swapping: a mechanism for oligomer assembly. Protein Sci. 4, 2455-2468.
6. Kelly, J.W. (1996). Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11-17.
7. Kelly, J.W. & Lansbury, P.T.J. (1994). A chemical approach to elucidate the mechanism of transthyretin and beta-protein amyloid fibril formation. Amyloid - Int. J. Exp. Clin. Invest. 1, 186-205.
8. Wetzel, R. (1996). For protein misassembly, its the "I" decade. Cell 86, 699-702.
9. Jarrett, J. & Lansbury, P.T. (1993). Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie ? Cell 73, 1055-1058.
10. Thomas, P.J., Qu, B.-H. & Pederson, P.L. (1995). Defective protein folding as a cause of human disease. Trends Biochem. Sci. 20, 456-459.
11. Booth, D.R., et al., & Pepys, M.B. (1997). Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793.
12. Hurle, M.R., Helms, L.R., Li, L., Chan, W. & Wetzel, R. (1994). A role for destabilizing amino acid replacements in light chain amyloidosis. Proc. Natl. Acad. Sci. USA 91, 5446-5450.
13. Lansbury, P.T. (1995). The chemistry of the scrapie infection: implications of the ICE 9 metaphor. Chem. Biol. 2, 1-5.
14. Bessen, R.A., Kocisko, D.A., Raymond, G.J., Nandan, S., Lansbury, P.T. & Caughey, B. (1995). Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 375, 698-700.
15. Kocisko, D.A., Priola, S.A., Raymond, G.J., Chesebro, B., Lansbury, P.T., Jr. & Caughey, B. (1995). Species specificity in the cell free conversion of prion protein to protease-resistant forms: a model for the scrapies species barrier. Proc. Natl. Acad. Sci. USA 9, 3923-3927.
16. Zhang, H., et al., & Prusiner, S.B. (1995). Conformational transitions on peptides containing two putative alpha-helices of the prion protein. J. Mol. Biol. 250, 514-526.
17. Pan, K.M., et al., & Cohen, F.E. (1993). Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 90, 10962-10966.
18. Patino, M.M., Liu, J.J., Glover, J.R. & Lindquist, S. (1996). Support for the prion hypothesis for inheritance of a phenotypic trait in yeast. Science 273, 622-626.
19. Lindquist, S. (1996). Mad cows meet mad yeast: the prion hypothesis. Mol. Psychiatry 1, 376-379.
20. Lindquist, S. (1997). Mad cows meet psi-chotic yeast: the expansion of the prion hypothesis. Cell, in press.
21. Wetzel, R. (1992). Protein aggregation in vivo: bacterial inclusion bodies and mammalian amyloid. In Stability of Protein Pharmaceuticals: in vivo Pathways of Degradation and Strategies for Protein Stabilization. (Ahern, T. & Manning, M., Eds), pp. 43-88, Plenum Press, NY.
22. Wetzel, R. (1994). Mutations and off-pathway aggregation of proteins. Trends in Biotech. 12, 193-198.
23. Eaton, W.A. & Hofrichter, J. (1990). Sickle cell hemoglobin polymerization. Adv. Protein Chem. 40, 63-279.
24. Cohen, A.S., Shirahama, T. & Skinner, M. (1982). Electron microscopy of amyloid. In Electron Microscopy of Proteins. (Harris, L.R., Ed), pp. 165-205, Academic Press, London.
25. Tan, S.Y. & Pepys, M.B. (1994). Amyloidosis. Histopathology 25, 403-414.
26. Colon, W. & Kelly, J.W. (1991). Transthyretin acid induced denaturation is required for amyloid fibril formation in vitro. In Applications of Enzyme Biotechnology. (Kelly J.W. & Balwin, T.O., eds), pp. 99-108, Plenum Press, NY.
27. Colon, W. & Kelly, J.W. (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660.
28. Gustavsson, A., Engstrom, U. & Westermark, P. (1991). Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro. Biochem. Biophys. Res. Comm. 175, 1159-1164.
29. Lai, Z., Colon, W. & Kelly, J.W. (1996). The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate which can self-assemble into amyloid. Biochemistry 35, 6470-6482.
30. Lai, Z., Lashuel, H.A. & Kelly, J.W. (1997). Characterization of the transthyretin acid denaturation pathway by analytical ultracentrifugation: implications for amyloid fibril formation. Biochemistry, in press.
31. Lai, Z., McCulloch, J. & Kelly, J.W. (1997). GdnHCl induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Biochemistry, in press.
32. Colon, W., et al., & Kelly, J.W. (1997). Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid: a new therapeutic strategy based on preventing the amyloidogenic conformational changes. In Protein Misassembly. (Wetzel, R., ed), Academic Press, New York.
33. McCutchen, S.L., Lai, Z., Miroy, G., Kelly, J.W. & Colon, W. (1995). Comparison of lethal and non-lethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34, 13527-13536.
34. McCutchen, S., Colon, W. & Kelly, J.W. (1993). Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 32, 12119-12127.
35. Lomakin, A., Chung, D.S., Benedek, G.B., Kirschner, D.A. & Teplow, D.B. (1996). On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantification of rate constants. Proc. Natl. Acad. Sci. USA 93, 1125-1129.
36. Snyder, S.W., et al., & Holzman, T.F. (1994). Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67, 1216-1228.
37. Shen, C.-L. & Murphy, R.M. (1995). Solvent effects on self-assembly of beta-peptide. Biophys. J. 69, 640-651.
38. Shen, C.L., Fitzgerald, M.C. & Murphy, R.M. (1995). Effect of acid predissolution on fibril size and fibril flexibility of synthetic beta-amyloid peptide. Biophys. J. 67, 1238-1246.
39. Harper, J.D., Wong, S.S., Lieber, C.M. & Lasbury, P.T. (1997). Observation of metastable A-beta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125.
40. Stine, W.B., et al., Krafft, G.A. (1996). The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy J. Prot. Chem. 15, 193-203.
41. Jacobson, D.R. & Buxbaum, J.N. (1991). Genetic aspects of amyloidosis. Adv. Hum. Genet. 20, 69-123.
42. Tan, S.Y., Pepys, M.B. & Hawkins, P.N. (1995). Treatment of amyloidosis. Am. J. Kidney Dis. 26, 267-285.
43. Pepys, M.B. (1988). Amyloidosis. In Immunological Diseases. (Samter, M., ed), pp. 631-674, Little, Brown and Company, Boston.
44. Benson, M.D. & Wallace, M.R. (1989). Amyloidosis in the Metabolic Basis of Inherited Disease. (Scriver, C.R., Stanbury, J.B., Wyngaarden, J.B. & Fredrickson, D.S., eds), pp. 2439-2460, McGraw Hill, NY.
45. Benson, M.D. (1989). Familial amyloidotic polyneuropathy. Trends Biochem. Sci. 12, 88-92.
46. Sipe, J.D. (1992). Amyloidosis. Ann. Rev. Biochem. 61, 947-975.
47. Sipe, J.D. (1994). Amyloidosis. Crit. Rev. Clin. Lab. Sci. 31, 325-354.
48. Saraiva, M.J.M., Costa, P.P. & Goodman, D.S. (1988). Transthyretin (prealbumin) in familial amyloidotic polyneuropathy: genetic and functional aspects. Adv. Neurol. 48, 189-200.
49. Cornwell, G.C., Sletten, K., Johansson, B. & Westermark, P. (1988). Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochem. Biophys. Res. Comm. 154, 648-653.
50. Westermark., P., Sletten, K., Johansson, B. & Cornwell, G.G. (1990). Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 87, 2843-2845.
51. Saravia, M.J.M., Birken, S., Costa, P. & Goodman, D.S. (1984). Amyloid fibril protein in familial polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). J. Clin Inv. 74, 104-119.
52. Sakaki, Y., Yoshioka, K., Tanahashi, H., Furuya, H. & Sasaki, H. (1989). Human transthyretin (prealbumin) gene and molecular genetics of familial amyloid polyneuropathy. Mol. Biol. Med. 6, 161-168.
53. Saraiva, M.J.M. (1995). Transthyretin Mutations in Health and Disease. Human Mutation 5, 191-196.
54. Matthews, B.W. (1993). Structural and genetic analysis of protein stability. Ann. Rev. Biochem. 62, 139-160.
55. Blake, C.C.F., Geisow, M.J., Swan, I.D.A., Rerat, C. & Rerat, B. (1974). Structure of human plasma prealbumin at 2.5 angstrom resolution. J. Mol. Biol. 88, 1-12.
56. Blake, C.C.F., Geisow, M.J. & Oatley, S.J. (1978). Structure of prealbumin: secondary, tertiary and quaternary interactions determined by fourier refinement at 1.8 Angstroms. J. Mol. Biol. 121, 339-356.
57. Terry, C.J., et al., & Blake, C.C.F. (1993). Crystral structure of recombinant Met 30 transthyretin suggests a molecular basis for amyloidogenesis in familiar amyloidotic polyneuropathy (FAP). EMBO J. 12, 735-741.
58. Hamilton, J.A., et al., & Steen, L. (1992). Alteration in molecular structure which results in disease: the Met-30 variant of human plasma transthyretin. Biochim. Biophys. Acta. 1139, 9-16.
59. Damas, A.M., Ribeiro, S., Lamzin, V.S., Palha, J.A. & Saraiva, M.J. (1996). Structure of the Val122lie variant transthyretin-A cardiomyopathic mutant. Acta Cryst. D 52, 966-972.
60. Steinrauf, L.K., Hamilton, J.A., Braden, B.C., Murrel, J.R. & Benson, M.D. (1993). X-ray crystal structure of the Ala-109-Thr variant of human transthyretin which produces euthyroid hyperthyroxinemia. J. Biol. Chem. 268, 2425-2430.
61. Agard, D.A. (1993). To fold or not to fold (the box model). Science 260, 1903-1904.
62. King, J. (1986). Genetic analysis of protein folding pathways. Bio/Technology 4, 297-303.
63. Holtzman, E. (1989). Lysosomes. In Cellular Organelles.(Siekevitz, P., ed), pp. 216-220, Plenum Press, NY.
64. Alexandrescu, A.T., Evans, P.A., Pitkeathly, M., Baum, J. & Dobson, C.M. (1993). Structure and dynamics of the acid denatured molten globule state of α-lactalbumin: a two-dimensional NMR study. Biochemistry 32, 1707-1718.
65. Neri, D., Billeter, M., Wider, G. & Wuthrich, K. (1992). NMR determination of residual structure in a urea denatured protein, the 434 Trp-repressor. Science 257, 1559-1563.
66. Fan, P., Bracken, C. & Baum, J. (1993). Structural characterization of monellin in the alcohol denatured state by NMR: evidence for γ-sheet to α-helix conversion. Biochemistry 32, 1573-1582.
67. Serpell, L.C., et al., & Blake, C.C.F. (1995). Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. J. Mol. Biol. 254, 113-118.
68. Blake, C.C.F., Serpell, L.C., Sunde, M., Sandgren, O. & Lundgren, E. (1996). A molecular model of the amyloid fibril. In The Nature and Origin Of Amyloid Fibrils. (Bock, G.R.G., Goode, J.A. eds), pp. 6-21, John Wiley and Sons, Chichester, UK.
69. Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R. & Wuthrich, K. (1996). NMR Structure of the mouse prion protein domain PRP (121-231). Nature 382, 180-182.
70. Lansbury, P.T., et al., & Griffin, R.G. (1995). Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel beta-sheet comprising a C-terminal peptide. Nat. Struct. Biol. 2, 990-998.
71. Inouye, H., Fraser, P.E.& Kirschner, D.A. (1993). Structure of betacrystallites assemblies formed by the Alzheimer beta-amyloid protein analogs: analysis by X-ray diffraction. Biophys. J. 64, 502-519.
72. Miroy, G.J., Lai, Z., Lashuel, H., Peterson, S.A., Strang, C.& Kelly, J.W. (1996). Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA 93, 15051-15056.
73. Blaney, J.M., et al., & Blake, C.C.F. (1982). Computer graphics in drug design: molecular modeling of thyroid hormone-prealbumin interactions. J. Med. Chem. 25, 785-790.